Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide

Open access
Wick, Wolfgang, Roth, Patrick, Hartmann, Christian, Hau, Peter, Nakamura, Makoto, Stockhammer, Florian, Sabel, Michael C., Wick, Antje, Koeppen, Susanne, Ketter, Ralf, Vajkoczy, Peter, Eyupoglu, Ilker, Kalff, Rolf, Happold, Caroline, Galldiks, Norbert, Schmidt-Graf, Friederike, Bamberg, Michael, Reifenberger, Guido, Platten, Michael, von Deimling, Andreas, Meisner, Christoph, Wiestler, Benedikt, Weller, Michael·2016·Neuro-Oncology

Abstract

Optimal treatment and precise classification for anaplastic glioma are needed. The objective for long-term follow-up of NOA-04 is to optimize the treatment sequence for patients with anaplastic gliomas. Patients were randomized 2:1:1 to receive the standard radiotherapy (RT) (arm A), procarbazine, lomustine and vincristine (PCV) (arm B1), or temozolomide (TMZ) (arm B2). Primary endpoint was time-to-treatment-failure (TTF), defined as progression after 2 lines of therapy or any time before if no further therapy was administered. Exploratory analyses examined associations of molecular marker status with TTF, progression-free survival (PFS), and overall survival (OS). At 9.5 (95% CI: 8.6–10.2) years, no difference between arms (A vs B1/B2) was observed: median TTF (4.6 [3.4–5.1] y vs 4.4 [3.3–5.3) y), PFS (2.5 [1.3–3.5] y vs 2.7 [1.9–3.2] y), and OS (8 [5.5–10.3] y vs 6.5 [5.4–8.3] y). Oligodendroglial versus astrocytic histology—but more so the subgroups according to CpG island methylator phenotype (CIMP) and 1p/19q co-deletion status—revealed a strong prognostic value of CIMPpos with (CIMPcodel) versus without 1p/19 co-deletion (CIMPnon-codel) versus CIMPneg. but no differential efficacy of RT versus chemotherapy for any of the endpoints. PFS was better for PCV- than for TMZ-treated patients with CIMPcodel tumors (HR B1 vs B2 0.39 [0.17–0.92], P = .031). In CIMPneg. tumors, hypermethylation of the O6-methyl-guanyl-DNA methyltransferase promoter (MGMT) provided a risk reduction for PFS with chemotherapy. There is no differential activity of primary chemotherapy versus RT in any subgroup of anaplastic glioma. Molecular diagnosis is superior to histology. Trial Registration: clinicaltrials.gov Identifier: NCT00717210.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/neuonc/now133

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 227

Metadata

Authors
Wick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., Sabel, M. C., Wick, A., Koeppen, S., Ketter, R., Vajkoczy, P., Eyupoglu, I., Kalff, R., Happold, C., Galldiks, N., Schmidt-Graf, F., Bamberg, M., Reifenberger, G., Platten, M., von Deimling, A., Meisner, C., Wiestler, B., & Weller, M.
Venue
Neuro-Oncology
Published
2016-07-01
Volume
18
Issue
11
Pages
now133
ISSN
  • 1522-8517 (ISSN-L)
  • 1523-5866
OpenAlex
W2460821456
Cited by
227
References
2
FWCI
17.03
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. https://app.cochat.ai/papers/10.1093/neuonc/now133
The paper
Wick, W., Roth, P., Hartmann, C., Hau, P., Nakamura, M., Stockhammer, F., Sabel, M. C., Wick, A., Koeppen, S., Ketter, R., Vajkoczy, P., Eyupoglu, I., Kalff, R., Happold, C., Galldiks, N., Schmidt-Graf, F., Bamberg, M., Reifenberger, G., Platten, M., . . . Weller, M. (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology. https://doi.org/10.1093/neuonc/now133

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.